Search for companies, drugs, and catalysts
Phase 3
Development Phase
1
Upcoming Catalysts
0
Historical Events
Regulatory Approvals
KB803 Phase 3 Results Expected
KB803 • Dystrophic Epidermolysis Bullosa
Target Indication
Dystrophic Epidermolysis Bullosa
Clinical Trial
Last updated: 12/4/2025
KRYS
Krystal Biotech, Inc.